Tolerability and Patient Factors Influence Use of Dual IO in Melanoma
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The use of dual immune-oncology therapy in melanoma is influenced by tolerability and patient factors. Comorbidities may limit the use of this treatment approach in some patients with advanced melanoma. The role of dual immune-oncology therapy is also being considered in other cancers, such as renal cell carcinoma.